Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA

L. Kostakoglu, M. Martelli, LH. Sehn, D. Belada, AM. Carella, N. Chua, E. Gonzalez-Barca, X. Hong, A. Pinto, Y. Shi, Y. Tatsumi, A. Knapp, F. Mattiello, T. Nielsen, D. Sahin, G. Sellam, MZ. Oestergaard, U. Vitolo, M. Trněný

. 2021 ; 5 (5) : 1283-1290. [pub] 20210309

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019073

GOYA was a randomized phase 3 study comparing obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) vs standard-of-care rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). This retrospective analysis of GOYA aimed to assess the association between progression-free survival (PFS) and overall survival (OS) with positron emission tomography (PET)-based complete response (CR) status. Overall, 1418 patients were randomly assigned to receive 8 21-day cycles of obinutuzumab (n = 706) or rituximab (n = 712) plus 6 or 8 cycles of CHOP. Patients received a mandatory fluoro-2-deoxy-d-glucose-PET/computed tomography scan at baseline and end of treatment. After a median follow-up of 29 months, the numbers of independent review committee-assessed PFS and OS events in the entire cohort were 416 (29.3%) and 252 (17.8%), respectively. End-of-treatment PET CR was highly prognostic for PFS and OS according to Lugano 2014 criteria (PFS: hazard ratio [HR], 0.26; 95% confidence interval [CI], 0.19-0.38; P < .0001; OS: HR, 0.12; 95% CI, 0.08-0.17; P < .0001), irrespective of international prognostic index score and cell of origin. In conclusion, the results from this prospectively acquired large cohort corroborated previously published data from smaller sample sizes showing that end-of-treatment PET CR is an independent predictor of PFS and OS and a promising prognostic marker in DLBCL. Long-term survival analysis confirmed the robustness of these data over time. Additional meta-analyses including other prospective studies are necessary to support the substitution of PET CR for PFS as an effective and practical surrogate end point. This trial was registered at www.clinicaltrials.gov as #NCT01287741.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019073
003      
CZ-PrNML
005      
20210830100639.0
007      
ta
008      
210728s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/bloodadvances.2020002690 $2 doi
035    __
$a (PubMed)33651099
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kostakoglu, Lale $u Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA
245    10
$a End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA / $c L. Kostakoglu, M. Martelli, LH. Sehn, D. Belada, AM. Carella, N. Chua, E. Gonzalez-Barca, X. Hong, A. Pinto, Y. Shi, Y. Tatsumi, A. Knapp, F. Mattiello, T. Nielsen, D. Sahin, G. Sellam, MZ. Oestergaard, U. Vitolo, M. Trněný
520    9_
$a GOYA was a randomized phase 3 study comparing obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) vs standard-of-care rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). This retrospective analysis of GOYA aimed to assess the association between progression-free survival (PFS) and overall survival (OS) with positron emission tomography (PET)-based complete response (CR) status. Overall, 1418 patients were randomly assigned to receive 8 21-day cycles of obinutuzumab (n = 706) or rituximab (n = 712) plus 6 or 8 cycles of CHOP. Patients received a mandatory fluoro-2-deoxy-d-glucose-PET/computed tomography scan at baseline and end of treatment. After a median follow-up of 29 months, the numbers of independent review committee-assessed PFS and OS events in the entire cohort were 416 (29.3%) and 252 (17.8%), respectively. End-of-treatment PET CR was highly prognostic for PFS and OS according to Lugano 2014 criteria (PFS: hazard ratio [HR], 0.26; 95% confidence interval [CI], 0.19-0.38; P < .0001; OS: HR, 0.12; 95% CI, 0.08-0.17; P < .0001), irrespective of international prognostic index score and cell of origin. In conclusion, the results from this prospectively acquired large cohort corroborated previously published data from smaller sample sizes showing that end-of-treatment PET CR is an independent predictor of PFS and OS and a promising prognostic marker in DLBCL. Long-term survival analysis confirmed the robustness of these data over time. Additional meta-analyses including other prospective studies are necessary to support the substitution of PET CR for PFS as an effective and practical surrogate end point. This trial was registered at www.clinicaltrials.gov as #NCT01287741.
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a lidé $7 D006801
650    12
$a difúzní velkobuněčný B-lymfom $x diagnostické zobrazování $x farmakoterapie $7 D016403
650    12
$a PET/CT $7 D000072078
650    _2
$a pozitronová emisní tomografie $7 D049268
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Martelli, Maurizio $u Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
700    1_
$a Sehn, Laurie H $u BC Cancer Center for Lymphoid Cancer and the University of British Columbia, Vancouver, BC, Canada
700    1_
$a Belada, David $u 4th Department of Internal Medicine-Hematology, Faculty of Medicine, Charles University, Hradec Králové, Czech Republic
700    1_
$a Carella, Angelo-Michele $u Hematology and Bone Marrow Transplantation Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Martino, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
700    1_
$a Chua, Neil $u Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
700    1_
$a Gonzalez-Barca, Eva $u Institut Català d'Oncologia, Institut d'Investigació Biomédica de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
700    1_
$a Hong, Xiaonan $u Fudan University Shanghai Cancer Center, Shanghai, China
700    1_
$a Pinto, Antonio $u Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples, Italy
700    1_
$a Shi, Yuankai $u Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
700    1_
$a Tatsumi, Yoichi $u Kinki University Hospital, Osaka, Japan
700    1_
$a Knapp, Andrea $u F. Hoffmann-La Roche, Ltd, Basel, Switzerland
700    1_
$a Mattiello, Federico $u F. Hoffmann-La Roche, Ltd, Basel, Switzerland
700    1_
$a Nielsen, Tina $u F. Hoffmann-La Roche, Ltd, Basel, Switzerland
700    1_
$a Sahin, Deniz $u F. Hoffmann-La Roche, Ltd, Basel, Switzerland
700    1_
$a Sellam, Gila $u F. Hoffmann-La Roche, Ltd, Basel, Switzerland
700    1_
$a Oestergaard, Mikkel Z $u F. Hoffmann-La Roche, Ltd, Basel, Switzerland
700    1_
$a Vitolo, Umberto $u Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia, IRCCS, Turin, Italy; and
700    1_
$a Trněný, Marek $u 1st Department of Medicine, 1st Faculty of Medicine, Charles University General Hospital, Prague, Czech Republic
773    0_
$w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 5, č. 5 (2021), s. 1283-1290
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33651099 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100639 $b ABA008
999    __
$a ok $b bmc $g 1689994 $s 1139519
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 5 $c 5 $d 1283-1290 $e 20210309 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace